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SUMMARY. Crohn’s disease occurs at any part of gastro-intestinal tract (GIT) but the most susceptible is
the ileo-cecal region. For an effective treatment of this disease is essential the drug to be released at ileo-ce-
cal region for an extended period of time. The present study is an attempt to design and develop an ileo-ce-
cal targeting mucoadhesive drug delivery system that may be released specifically and slowly in ileo-cecal
region without being released in the upper GIT for an extended period of time (12 h). Budesonide mucoad-
hesive tablets are coated with Eudragit S100, which is a polymer that specifically dissolves at and above
pH 6.8. The in vitro drug release by changing pH method was done and in vivo study using X-ray radiogra-
phy was carried out to ascertain the position of tablets in GIT after specific time intervals. The in vitro
performance of the tablet with 10 % w/w coating level showed that the tablet did not disintegrate till 16 h
with constant drug release. An in vivo study also reveals that the tablet lasted till 16 h in the ileo-cecal re-
gion. 
